Laboratorios Farmaceuticos Rovi, S.A. will propose to the General Shareholders' Meeting a dividend of EUR 1.2938 per share charged to the 2022 profit and retained earnings. This proposed dividend would mean an increase of 35% on the dividend charge to the 2021 profit and represents the same 35% of the net profit for 2022 attributed to the parent company.